Page 1

همه maravai Life Sciences Maravai Lifesciences Reports First Quarter Financial Results and Updates 2021 Financial Guidance May 10 , 2021 SAN DIEGO , May 10 , 2021 ( GLOBE NEWSWIRE ) -- Maravai Life Sciences Holdings , Inc. ( Maravai ) ( NASDAQ : MRVI ) , a global provider of life science reagents and services to researchers and biotech innovators , today reported financial results for the first quarter ended March 31 , 2021 . Highlights include : • Revenue increased 190.7 % to $ 148.2 million for the first quarter ; ● Updated 2021 revenue guidance of $ 680.0 million to $ 720.0 million , representing full year growth of 139.4 % to 153.5 % . " As reported in our pre - announcement , Maravai's strong momentum continued in the first quarter of 2021 , primarily driven by the continued strength of our Nucleic Acid Production business , " said Carl Hull , Chairman and CEO . " I am very proud of the ways in which our extraordinary team , and our partners , continue to scale meaningfully to address the global COVID - 19 pandemic . We are pleased to be able to report exceptionally strong quarterly results and to provide updated financial guidance , " added Hull . Revenue for the First Quarter of Fiscal 2021 Revenue Nucleic Acid Production Biologics Safety Testing Protein Detection Total revenue $ $ 2021 Three Months Ended March 31 , 123,932 $ 17,649 6,630 148,211 $ 2020 30,490 14,293 6,198 50,981 Year - over - Year % Change 306.5 % 23.5 % 7.0 % 190.7 % First Quarter Fiscal 2021 Financial Results Revenue for the first quarter was $ 148.2 million , representing a 190.7 % increase over the same period prior year and was driven by the following : . Nucleic Acid Production reven was $ 123.9 million for the first quarter , repr ing a 306.5 % increase year - over - year . The increase in Nucleic Acid Production revenue was driven by : continued strong demand for our proprietary CleanCapⓇ analogs as COVID - 19 vaccine manufacturers scale production ; increasing demand for highly - modified RNA products , particularly mRNA , due to resumption of mRNA therapeutic programs ; and lifting of shelter - in - place COVID - 19 restrictions . • Biologic Safety Testing revenue was $ 17.6 million for the first quarter , representing a 23.5 % increase year - over - year . The increase was driven by higher demand and consumption of our products as a result of increased COVID - 19 related diagnostic needs ; and increased demand for contract services . • Protein Detection revenue was $ 6.6 million for the first quarter , representing a 7.0 % increase year - over - year . The increase was primarily due to the resumption of research laboratory work from prior shutdowns as a result of the COVID - 19 pandemic , coupled with increased demand for our products . Net income and Adjusted EBITDA ( non - GAAP ) were $ 75.9 million and $ 101.9 million , respectively , for the first quarter of 2021 , compared to $ 23.9 million and $ 29.6 million for the first quarter of the prior year . Updated Financial Guidance for 2021 Our updated financial guidance for the full year 2021 is based on expectations for our existing business and does not include the financial impact of potential new acquisitions , if any , or items that have not yet been identified or quantified . This guidance is subject to a number of risks and uncertainties identified in the Forward - Looking Statements below . Total revenue is projected to be in the range of $ 680.0 million to $ 720.0 million , reflecting overall growth of 139.4 % to 153.5 % . Adjusted EBITDA ( non - GAAP ) is expected to be in the range of $ 440.0 million to $ 470.0 million . Adjusted fully diluted EPS ( non - GAAP ) is expected to be in the range of $ 1.04 - $ 1.12 per share . Adjusted fully diluted EPS ( non - GAAP ) is based on the assumption that all Class B shares are converted to Class A shares . The net income ( loss ) included in the Adjusted fully diluted EPS ( non - GAAP )